BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) presented new biomarker data from the Phase 3 trial of its late-stage investigational amyotrophic lateral sclerosis (ALS) treatment, NurOwn, at the 2023 ALS and Related Motor Neuron Diseases
Related Keywords
, Gordon Research Conference , Brainstorm Cell Therapeutics Inc , Related Motor Neuron Diseases , Gordon Research , Central Nervous System Drugs Advisory Committee ,
comparemela.com © 2020. All Rights Reserved.